Thu, Jul 24, 2014, 5:35 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Mylan, Inc. Message Board

  • jhatka jhatka Jan 23, 1998 1:02 PM Flag

    bail out

    my suggestion is to bail out while you can.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • it was a great story and i made a killing trading it but because
      of frost look at it now.
      k2b1

    • symbol is ivx listed on amse company scares me in my opinion no comparison to myl you be the judge!!

    • No such ticker symbol

    • mr saks couldnt find his way to the kitchen.
      k2b1

    • interactive about myl dated Jan. 26. could k2b1 be blowing smoke again? wall st. journal did have a recent article favorable on generics and myl:

      The Wall Street Journal -- January 19, 1998
      Generic-Drug Firms Are Seen
      Posting
      Healthy Results for the Fourth
      Quarter

      ----

      By Jennifer Fron Mauer
      Dow Jones Newswires

      NEW YORK -- Improved pricing, continued cost-cutting and new-drug
      approvals helped boost fourth-quarter profits at most generic-drug makers.

      After heavier-than-usual discounting in 1996, most of the companies kept
      prices firmer last year, analysts said. David Saks, an analyst at Gruntal &
      Co., said the discounting averaged 7% to 9% in 1997, compared with 15%
      to 25% in 1996.

      "Pricing is the best it's been in years," Mr. Saks added.

      SBC Warburg Dillon Read & Co. analyst Jerry Treppel said earnings at
      generic-drug companies also are benefiting from cost-cutting.

      In addition, the industry has seen an increase in new-drug approvals. Mr.
      Saks said the U.S. Food and Drug Administration approved 240 generic
      drugs in 1997, up from 190 in 1996 and nearly twice the 122 it approved in
      1994.

      Only Ivax Corp., which is in the midst of a lengthy restructuring, is expected
      to turn in a poor fourth-quarter performance. Analysts estimate the Miami
      company's losses widened to 34 cents a share from two cents in fourth
      quarter of 1996, according to estimates compiled by First Call Corp.

      Mylan Laboratories Inc., of Pittsburgh, which just completed its fiscal third
      quarter, is expected to earn 24 cents a share, up from 15 cents a year
      earlier, First Call said. Independent analyst Hemant Shah said Mylan
      continues to benefit from sales of its generic version of the ulcer-treatment
      drug Zantac.

      Watson Pharmaceutical Inc. of Corona, Calif., known for making narcotic
      pain-killers, is seen earning 32 cents a share in the fourth quarter, compared
      with a split-adjusted 26 cents a year earlier.

      Israel's Teva Pharmaceutical Industries Ltd. is expected to earn 64 cents
      per American depositary receipt, up from 43 cents, excluding a write-off, a
      year ago.

      The biggest improvement is expected to come from Alpharma Inc. Analysts
      estimate the Fort Lee, N.J., company earned 24 cents a share, compared
      with a loss of 36 cents, excluding charges, a year earlier, First Call said.

      With only a limited number of brand-name drugs coming off patent during
      the next two years, analysts said, generic-drug makers are looking further
      ahead. In the first years of the new century, makers of some of the nation's
      best-known prescription drugs will lose their patents, exposing them to
      competition from generic companies.

      Mr. Saks predicted "2000 to 2003 will be boom time in Genericville."
      However, he said, the expiration of patents is merely an opportunity.
      Generic-drug companies must be prepared to exploit it when it comes, or
      risk losing it altogether.

    • I don't know who k2b1 and octavious are trying to kid. They are
      one and the same. Even their spellings and grammatical errors are alike. Some kind of broken english. But the perfect stock pickers...ha, ha.

    • If you are lookig for a turn around story, check out IVAX..

    • since i am not a subscriber of barrons this is of little value what is plan B for short interest in stocks on NYSE?

    • he's just telling you what he thinks you want to hear.
      have you ever planted a tree in the back yard? did you
      go out measuring its growth every day? this week its at
      18 feet but last week it was at 19.5 feet? very strange.
      could it just be the wind blowing it a little? it won't
      break. it is an oak. and it is still growing regardless
      of what your little stick says today. we'll fall asleep for
      six or eight months and go out back and it will be 28-30 feet
      by then. listen. you can hear it growing. why keep digging
      it up and replanting it? makes no sense.

    • where did you get that from english literature 202?
      were talking more than nickels.
      k2b1

    • View More Messages
 
MYL
51.90-0.44(-0.84%)Jul 24 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.